David Holloway, MD
Psychiatry · Waukesha, WINPI 1821195777
Payments from drug & device makers
Across 949 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Lundbeck LLC$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Vanda Pharmaceuticals Inc.$889
- plus $5K from 25 others
What the payments were for
- Food & beverage$14,16099%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 175 | $2,134 |
| Lundbeck LLC | 136 | $2,020 |
| AbbVie(2 entities) | 148 | $1,884 |
| Otsuka America Pharmaceutical, Inc. | 83 | $1,343 |
| Neurocrine Biosciences, Inc. | 50 | $1,073 |
| Vanda Pharmaceuticals Inc. | 64 | $889 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $688 |
| Johnson & Johnson | 30 | $508 |
| Teva Pharmaceuticals USA, Inc. | 20 | $425 |
| Axsome Therapeutics, Inc. | 27 | $398 |
| Almatica Pharma LLC | 22 | $349 |
| Corium, LLC | 19 | $348 |
| Bausch Health US, LLC | 19 | $312 |
| E.r. Squibb & Sons, L.L.C. | 13 | $286 |
| Ironshore Pharmaceuticals Inc. | 17 | $228 |
| Adlon Therapeutics L.p. | 15 | $211 |
| Shire North American Group Inc | 16 | $195 |
| Alkermes, Inc. | 10 | $188 |
| Supernus Pharmaceuticals, Inc. | 7 | $116 |
| Tris Pharma Inc | 5 | $100 |
| Idorsia Pharmaceuticals US Inc | 5 | $78 |
| Noven Therapeutics, LLC | 4 | $76 |
| Sage Therapeutics, LLC | 3 | $73 |
| Jazz Pharmaceuticals Inc. | 5 | $73 |
| Harmony Biosciences LLC | 3 | $62 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| Neuronetics, Inc. | 3 | $32 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Neos Therapeutics, LP | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,237 in reported general payments places this provider in the 95th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 95 | $142,507 |
| Austedo XrDeutetrabenazine | 26 | $131,022 |
| RexultiBrexpiprazole | 57 | $93,862 |
| CaplytaLumateperone Tosylate | 13 | $22,657 |
| VyvanseLisdexamfetamine Dimesylate | 40 | $19,722 |
| AdderallDextroamphetamine/Amphetamine | 13 | $10,845 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 252 | $10,229 |
| TrintellixVortioxetine Hydrobromide | 19 | $9,340 |
| Lisdexamfetamine Dimesylate | 40 | $9,229 |
| Vilazodone Hcl | 84 | $9,000 |
| ViibrydVilazodone Hcl | 25 | $8,687 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 114 | $8,631 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 130 | $8,415 |
| Bupropion XlBupropion Hcl | 284 | $8,275 |
| Duloxetine Hcl | 316 | $7,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Viibryd | $1,884 | $151,194120 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $425 | $131,02226 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,343 | $93,86257 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Adderall, Trintellix | $2,134 | $39,90872 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $688 | $22,65713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Waukesha
- Cary KohlenbergWaukesha$90K
- James RutherfordWaukesha$36K
- Scott WienerGreenfield$1.4M
- Anne KoplinMadison$613K
- Joseph BergsRacine$346K
- Royle EenigenburgJuneau$344K
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Rise FuttererMadison$203K
- Joseph BurgarinoMilwaukee$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.